Trump Eyes 100% Tariffs on Some Imported Drugs to Push Prices Down
Trump Eyes 100% Tariffs on Some Imported Drugs to Push Prices Down
The administration weighs steep drug tariffs, up to 100%, for makers that don’t strike price-cut deals under a new TrumpRx.gov framework.
The White House is weighing a broad expansion of tariffs aimed at the pharmaceutical sector, potentially slapping up to 100% duties on imported branded and patented medicines that have not agreed to price-lowering commitments with the government. The plan is tied to a Section 232 investigation and a new TrumpRx.gov platform meant to encourage price concessions and boost domestic manufacturing.
Officials say the goal is to tilt the economics in favor of U.S. production and lower drug costs for patients, with exemptions possible for certain medicines and disease categories. Companies such as Pfizer and AstraZeneca have previously secured multi-year exemptions by pledging pricing deals, while others that do not reach agreements could face the steep tariffs. The specifics remain fluid and could change as negotiations continue.
Critics warn that tariffs could raise costs for patients and disrupt supply chains, while supporters argue that higher penalties will push pharma firms to bring more manufacturing onshore. The industry had been shielded from global tariffs enacted in 2025, which were later struck down by the Supreme Court, making the new approach more targeted but also more uncertain.
Authorities have signaled urgency, with reports suggesting a formal announcement could come as soon as Thursday if negotiations fail. Observers will be watching for how exemptions are defined, which drugs are covered, and how any new policies interact with broader healthcare reforms and trade talks.
